Applied DNA Sciences, Inc.

Equities

APDN

US03815U3005

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
0.333 USD -3.28% Intraday chart for Applied DNA Sciences, Inc. -15.53% -46.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Certain Warrants of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024. CI
Certain Options of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024. CI
Certain Common Stock of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024. CI
Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress CI
Applied DNA Sciences Files Prospectus for Potential Secondary Stock Offerings MT
Transcript : Applied DNA Sciences, Inc., Q1 2024 Earnings Call, Feb 08, 2024
Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q1 Revenue $891,164 MT
Applied DNA Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Applied DNA Sciences, Inc. Announces Joint Development Agreement to Integrate Linea IVT Platform into CDMO Kudo Biotechnology?s mRNA Manufacturing Workflow CI
HC Wainwright Cuts Price Target on Applied DNA Sciences to $2 From $4, Keeps Buy Rating MT
Transcript : Applied DNA Sciences, Inc., Q4 2023 Earnings Call, Dec 07, 2023
Earnings Flash (APDN) APPLIED DNA SCIENCES Posts Q4 Revenue $779,736, vs. Street Est of $1.7M MT
Applied DNA Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023 CI
Applied DNA Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Applied DNA Sciences, Inc. Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application CI
Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna) CI
Applied DNA Sciences, Inc. Advances Commercialization of Linea(TM) IVT Platform CI
Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs CI
Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit CI
Applied DNA Sciences Files Patent Applications for mRNA Production by Reducing Double-Stranded RNA MT
Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production CI
HC Wainwright Adjusts Price Target on Applied DNA Sciences to $4 From $5, Keeps Buy Rating MT
Transcript : Applied DNA Sciences, Inc., Q3 2023 Earnings Call, Aug 10, 2023
Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q3 Revenue $2.9M, vs. Street Est of $2.56M MT
Applied DNA Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Chart Applied DNA Sciences, Inc.
More charts
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.333 USD
Average target price
2.25 USD
Spread / Average Target
+575.68%
Consensus
  1. Stock Market
  2. Equities
  3. APDN Stock
  4. News Applied DNA Sciences, Inc.
  5. Applied DNA Sciences Unit Wins COVID-19 Testing Services Contract From NYC Client